Human Recombinant bFGF

Basic fibroblast growth factor

Human Recombinant bFGF

Basic fibroblast growth factor

From: 85 USD
Catalog #
(Select a product)
Basic fibroblast growth factor
Add to Wish List

Overview

Basic fibroblast growth factor (bFGF) is a prototypic member of the fibroblast growth factor family. Cytokines in the FGF family possess broad mitogenic and cell survival activities (Folkman & Klagsbrun; Kimelman & Kirschner) and are involved in a variety of biological processes including cell proliferation, differentiation, survival, and apoptosis (Folkman & Klagsbrun; Klagsbrun; Rifkin & Moscatelli). bFGF has the β-trefoil structure (Ponting & Russell), binds to the four FGF receptor (FGFR) family members, and activates JAK/STAT, PI3K, ERK1/2, and other receptor tyrosine kinase (RTK) signaling pathways. It supports the maintenance of undifferentiated human embryonic stem cells (Xu et al.; Kang et al.), stimulates human embryonic stem cells to form neural rosettes (Zhang et al.), and improves proliferation of human mesenchymal stem cells and enhances chondrogenic differentiation (Solchaga et al.).
Subtype
Cytokines, Growth Factors
Cell Type
Brain Tumor Stem Cells, Endoderm, PSC-Derived, Hematopoietic Stem and Progenitor Cells, Mesenchymal Stem and Progenitor Cells, Mesoderm, PSC-Derived, Neural Cells, PSC-Derived, Neural Stem and Progenitor Cells, Neurons, Pluripotent Stem Cells, Prostate Cells
Species
Human
Area of Interest
Epithelial Cell Biology, Neuroscience, Stem Cell Biology
Purity
less than 95%

Data Figures

(A) The biological activity of Human Recombinant bFGF was tested by its ability to promote the proliferation of BALB/c 3T3 cells. Cell proliferation was measured using a fluorometric assay method. The EC50 is defined as the effective concentration of the growth factor at which cell proliferation is at 50% of maximum. The EC50 in the above example is 0.1 ng/mL.
(B) 2 μg of Human Recombinant bFGF was resolved with SDS-PAGE under reducing (+) and non-reducing (-) conditions and visualized by Coomassie Blue staining. Human Recombinant bFGF has a predicted molecular mass of 17.1 kDa.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
78003.1, 78003, 78003.2
Lot #
All
Language
English
Document Type
Safety Data Sheet
Catalog #
78003.1, 78003, 78003.2
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Publications (1)

Retinoblastoma-binding proteins 4 and 9 are important for human pluripotent stem cell maintenance. O'Connor MD et al. Experimental hematology 2011 AUG

Abstract

OBJECTIVE: The molecular mechanisms that maintain human pluripotent stem (PS) cells are not completely understood. Here we sought to identify new candidate PS cell regulators to facilitate future improvements in their generation, expansion, and differentiation. MATERIALS AND METHODS: We used bioinformatic analyses of multiple serial-analysis-of-gene-expression libraries (generated from human PS cells and their differentiated derivatives), together with small interfering RNA (siRNA) screening to identify candidate pluripotency regulators. Validation of candidate regulators involved promoter analyses, Affymetrix profiling, real-time PCR, and immunoprecipitation. RESULTS: Promoter analysis of genes differentially expressed across multiple serial-analysis-of-gene-expression libraries identified E2F motifs in the promoters of many PS cell-specific genes (e.g., POU5F1, NANOG, SOX2, FOXD3). siRNA analyses identified two retinoblastoma binding proteins (RBBP4, RBBP9) as required for maintenance of multiple human PS cell types. Both RBBPs were bound to RB in human PS cells, and E2F motifs were present in the promoters of genes whose expression was altered by decreasing RBBP4 and RBBP9 expression. Affymetrix and real-time PCR studies of siRNA-treated human PS cells showed that reduced RBBP4 or RBBP9 expression concomitantly decreased expression of POU5F1, NANOG, SOX2, and/or FOXD3 plus certain cell cycle genes (e.g., CCNA2, CCNB1), while increasing expression of genes involved in organogenesis (particularly neurogenesis). CONCLUSIONS: These results reveal new candidate positive regulators of human PS cells, providing evidence of their ability to regulate expression of pluripotency, cell cycle, and differentiation genes in human PS cells. These data provide valuable new leads for further elucidating mechanisms of human pluripotency.